Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...

A DRUG that shrinks tumours in patients with untreatable prostate cancer has shown “remarkable” results, scientists have said ...

At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.

The new drug uses a so-called cloaking device and only activates when it reaches the tumour ...

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.

The thing that struck me hardest about prostate cancer wasn’t the diagnosis, it was the silence. Breast cancer, rightly, ...